To address the above‐mentioned gap, we evaluated the association between incomplete ART adherence with residual inflammation, immune activation, coagulopathy and vascular inflammation in treatment naïve PLHIV who initiated ART with CD4+ T cells >500 cells/mm3 and achieved viral suppression in the immediate arm of the Strategic Timing of Antiretroviral Treatment (START) study. This evidence concerns the gene CD4 and blood coagulation disease.